Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, DC. The poster entitled “Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of the Tumor and Its Immunosuppressive Microenvironment”, will be presented as part of the " Cellular Metabolism and Antitumor Immunity" session, on Friday, 09 November 2018 from 12:45 – 2:15 p.m. and from 6:30 – 8:00 p.m. Location: Walter E. Washington Convention Center, Exhibit Hall E, Abstract Poster Number: P197.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information please visit www.vidacpharma.com.
Contact: Shelly Majar +972-2-5952090
###
